Cue Biopharma (CUE) Asset Utilization Ratio (2018 - 2025)
Cue Biopharma (CUE) posted Asset Utilization Ratio of 0.41 for Q4 2025, up 107.29% sequentially from 0.2 in Q3 2025, and up 68.66% YoY from 0.24 in Q4 2024.
Cue Biopharma (CUE) Asset Utilization Ratio (2018 - 2025) Analysis & Trends
Cue Biopharma has reported Asset Utilization Ratio for 8 years, with the latest figure at 0.41 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 68.66% year-over-year to 0.41 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.41 (up 68.66% YoY) and the FY2025 annual result came in at 0.74, up 272.53% from the prior year.
- Asset Utilization Ratio climbed to 0.41 in Q4 2025 per CUE's latest filing, from 0.2 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.41 in Q4 2025 and troughed at 0.0 in Q1 2023.
- A 5-year average of 0.14 and a median of 0.13 in 2022 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio slumped 96.98% in 2023, then surged 2333.89% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.18 in 2021, then tumbled by 91.93% to 0.01 in 2022, then surged by 466.62% to 0.08 in 2023, then soared by 186.51% to 0.24 in 2024, then soared by 68.66% to 0.41 in 2025.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.41, 0.2, and 0.26 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 0.62 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.41 |
| Sep 30, 2025 | 0.20 |
| Jun 30, 2025 | 0.26 |
| Mar 31, 2025 | 0.29 |
| Dec 31, 2024 | 0.24 |
| Sep 30, 2024 | 0.22 |
| Jun 30, 2024 | 0.17 |
| Mar 31, 2024 | 0.12 |
| Dec 31, 2023 | 0.08 |
| Sep 30, 2023 | 0.05 |
| Jun 30, 2023 | 0.02 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 0.01 |
| Sep 30, 2022 | 0.12 |
| Jun 30, 2022 | 0.13 |
| Mar 31, 2022 | 0.17 |
| Dec 31, 2021 | 0.18 |
| Sep 30, 2021 | 0.08 |
| Jun 30, 2021 | 0.06 |
| Mar 31, 2021 | 0.04 |